Adult patients with locally advanced or metastatic solid tumors for which no standard therapy exists.
Conditions
Interventions
Sunitinib once every week or once every 2 weeks, at a starting dose of 200 mg
Sponsors
VU Medical Center
Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: 1. Signed (by the patient or legally acceptable representative) and dated Informed Consent Form 2. Histological or cytological documentation of incurable locally advanced or metastatic solid malignancy for which no standard therapy exists. 3. Primary tumor or metastatic site must be accessible for biopsy. Patients eligible for the expansion cohort must be willing to undergo tumor biopsies, while tumor biopsy remains optional for patients enrolled in the escalation cohort. Bone metastases are excluded as a biopsy site. 4. Evaluable disease by RECIST version 1.1 criteria (see appendix III; at least 1 target or non-target lesion for dose escalation cohorts; at least 1 target lesion for dose expansion cohort). 5. Patients must have documented radiographic or clinical progressive disease. 6. Age ≥ 18 years. 7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 8. Normal 12-lead ECG (clinically insignificant abnormalities permitted), and Left Ventricular Ejection Fraction (LVEF) > 50% by multigated acquisition (MUGA) scan or echocardiogram. 9. Normal regulated thyroid function- suppletion or blocking drugs permitted. 10. Urinalysis: no clinically significant abnormalities. 11. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to screening: a. Hemoglobin > 5.6 mmol/l b. Absolute neutrophil count (ANC) >1,5 x 10*9/l c. Platelet count  100 x 10*9/l d. Total bilirubin =50 ml/min (based on MDRD) h. PT-INR/PTT < 1.5 x ULN, unless coumarin derivatives are used i. Activated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation therapy is allowed, if this treatment can be interrupted for a biopsy as judged by the treating physician) Patients with known Gilbert’s disease who have serum bilirubin < x ULN may be enrolled. Pregnant or breast-feeding subjects: Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. For fertile men or women of childbearing potential: documented willingness to use a highly effective means of contraception (e.g., hormonal methods [implants, injectables, or combined oral contraceptives], intrauterine devices, sexual abstinence, or vasectomized or surgically sterilized partner). Contraception is necessary for at least 6 months after receiving the study kinase inhibitor.
Exclusion criteria
Exclusion criteria: 1. Evidence of a significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); nervous system, pulmonary (including obstructive pulmonary disease and history of symptomatic bronchospasm), renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture. 2. Poorly controlled hypertension despite adequate blood pressure medication. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements. 3. Seizure disorders requiring anticonvulsant therapy. 4. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery. 5. Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds.) 6. Known hypersensitivity to sunitinib or to its excipients. 7. Presence of any significant central nervous system or psychiatric disorder(s) that would interfere with the patient’s compliance. 8. Drug or alcohol abuse. 9. Females who are pregnant or breast-feeding. 10. Any evidence of a disease or condition that might affect compliance with the protocol or interpretation of the study results or render the patient at high risk from treatment complications. 11. Unwillingness or inability to comply with study and follow-up procedures. 12. No chemotherapy, radiotherapy, or biologic therapy within the previous 4 weeks; no nitrosoureas or mitomycin C within the previous 6 weeks; no investigational agents within the previous 4 weeks. 13. Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis. 14. Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control); 15. Patients with a history of treated CNS metastases are eligible, provided that all of the following criteria are met:  Presence of evaluable or measurable disease outside the CNS  Radiographic demonstration of improvement upon completion of CNS-directed therapy and no evidence of interim progression between completion of CNS-directed therapy and the screening radiographic study  Completion of radiotherapy ≥ 8 weeks prior to the screening radiographic study  Discontinuation of corticosteroids and anticonvulsants ≥ 4 weeks prior to the screening radiographic study. Note: Prior sunitinib therapy does not constitute an exclusion criterion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the maximum tolerated dose (MTD) of sunitinib when administered once a week or once every two weeks. - To assess the safety and tolerability of sunitinib in a once weekly or once every two weeks dose schedule | — |
Secondary
| Measure | Time frame |
|---|---|
| - To determine the pharmacokinetic (PK) behaviour of the parent compound sunitinib and the primary, active, metabolite SU12662. - Preliminary assessment of the efficacy of sunitinib intermittent treatment, administered at the MTD determined for each of the time schedules of the study (once weekly or once every two weeks). - To determine a recommended phase II dose (RP2D) and the optimal dose schedule - To determine the skin and intratumoral concentration of sunitinib and their correlation with the plasma concentration. - To assess immune/angiogenesis modulating systemic and local effects such as MDSC, Tregs and DC subset frequencies and tumor infiltrating leukocytes | — |
Contacts
Public ContactH.M.W. Verheul
De Boelelaan 1117
Outcome results
None listed